420 related articles for article (PubMed ID: 35803084)
21. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
22. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
23. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
Duan Y; Zhuo Z; Li H; Tian DC; Li Y; Yang L; Gao C; Zhang T; Zhang X; Shi FD; Barkhof F; Liu Y
J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):709-716. PubMed ID: 33687975
[TBL] [Abstract][Full Text] [Related]
24. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
25. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
Fujihara K; Cook LJ
Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
[TBL] [Abstract][Full Text] [Related]
26. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
[TBL] [Abstract][Full Text] [Related]
27. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
28. Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies.
Schwake C; Pakeerathan T; Kleiter I; Ringelstein M; Aktas O; Korporal-Kuhnke M; Wildemann B; Jarius S; Bayas A; Pul R; Ceylan U; Faissner S; Hellwig K; Ayroza Galvao Ribeiro Gomes AB; Lipps P; Pröbstel AK; Kümpfel T; Oswald E; Then Bergh F; Gödel C; Hümmert MW; Trebst C; Gold R; Ayzenberg I
Mult Scler; 2023 May; 29(6):757-761. PubMed ID: 36748649
[TBL] [Abstract][Full Text] [Related]
29. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
Xie H; Shao Y; Du J; Song Y; Li Y; Duan R; Yao Y; Gong Z; Teng J; Jia Y
J Neurol; 2022 Mar; 269(3):1641-1650. PubMed ID: 34383114
[TBL] [Abstract][Full Text] [Related]
31. Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.
Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
Mult Scler Relat Disord; 2021 Nov; 56():103222. PubMed ID: 34461572
[TBL] [Abstract][Full Text] [Related]
32. Modified models to distinguish central nervous system demyelinating diseases with brain lesions.
Chen B; Qin C; Ji S; Tian D; Zhang M; Bu B
Mult Scler Relat Disord; 2021 Jul; 52():102965. PubMed ID: 33905981
[TBL] [Abstract][Full Text] [Related]
33. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
Smith JB; Gonzales EG; Li BH; Langer-Gould A
JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry.
Newsome SD; Cross AH; Fox RJ; Halper J; Kanellis P; Bebo B; Li D; Cutter GR; Rammohan KW; Salter A
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34429342
[TBL] [Abstract][Full Text] [Related]
35. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
36. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
Akaishi T; Misu T; Fujihara K; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Nakashima I
J Neurol; 2022 Jun; 269(6):3136-3146. PubMed ID: 34820735
[TBL] [Abstract][Full Text] [Related]
37. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.
Pizzolato Umeton R; Waltz M; Aaen GS; Benson L; Gorman M; Goyal M; Graves JS; Harris Y; Krupp L; Lotze TE; Shukla NM; Mar S; Ness J; Rensel M; Schreiner T; Tillema JM; Roalstad S; Rodriguez M; Rose J; Waubant E; Weinstock-Guttman B; Casper C; Chitnis T;
Neurology; 2023 Feb; 100(9):e985-e994. PubMed ID: 36460473
[TBL] [Abstract][Full Text] [Related]
39. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.
Goldman-Yassen A; Lee A; Gombolay G
Pediatr Neurol; 2024 Apr; 153():125-130. PubMed ID: 38382244
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
